Paclitaxel induces apoptosis in leukemia cells through a JNK activation-dependent pathway

Area of Science:

• Molecular Biology
• Cancer Research
• Cell Biology

Background:

• Paclitaxel (PTX) is a key chemotherapy drug, but its precise anti-proliferation mechanisms remain unclear.
• Understanding PTX's molecular targets is vital for optimizing cancer therapy.

Purpose of the Study:

• To investigate the role of c-Jun N-terminal kinase (JNK) pathways in paclitaxel-induced apoptosis and proliferation inhibition.
• To elucidate the molecular events linking PTX treatment to cancer cell death.

Main Methods:

• Utilized human leukemia cell lines and primary chronic lymphocytic leukemia (CLL) cells.
• Employed flow cytometry, siRNA, mitochondrial membrane potential assays, and western blotting.
• Assessed cytochrome c release, caspase activation, and JNK pathway activity.

Main Results:

• Paclitaxel induced significant cytochrome c release, caspase 3 and PARP cleavage, and JNK activation in leukemia cells.
• JNK activation was upstream of cytochrome c release and caspase activation.
• Inhibiting JNK pathways blocked PTX-induced apoptosis and related molecular events.

Conclusions:

• JNK activation is a critical mediator of paclitaxel-induced apoptosis in leukemia.
• JNK signaling plays a pivotal role upstream of mitochondrial events and caspase activation in PTX's anti-cancer effects.